Travere Therapeutics Reports Fourth Quarter and Full Year 2020 Financial ResultsGlobeNewsWire • 03/01/21
Why Earnings Season Could Be Great for Travere Therapeutics (TVTX)Zacks Investment Research • 02/19/21
Travere Therapeutics Announces European Commission Has Granted Orphan Designation to Sparsentan for the Treatment of IgA NephropathyGlobeNewsWire • 02/18/21
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 02/17/21
Travere Therapeutics to Report Fourth Quarter and Full Year 2020 Financial ResultsGlobeNewsWire • 02/16/21
Ligand Partner Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental GlomerulosclerosisBusiness Wire • 02/02/21
Travere Therapeutics Shares Rally On Interim Sparsentan Data In Late-Stage Kidney Disorder StudyBenzinga • 02/02/21
Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental GlomerulosclerosisGlobeNewsWire • 02/02/21
Travere Therapeutics Announces Orphan Drug Designation for Sparsentan for the Treatment of IgA NephropathyGlobeNewsWire • 01/12/21
Are Options Traders Betting on a Big Move in Travere Therapeutics (TVTX) Stock?Zacks Investment Research • 12/30/20